{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:08:12Z","timestamp":1785787692082,"version":"3.56.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,7,27]]},"DOI":"10.1097\/01.tp.0000128611.71038.0c","type":"journal-article","created":{"date-parts":[[2004,7,21]],"date-time":"2004-07-21T04:05:12Z","timestamp":1090382712000},"page":"205-210","source":"Crossref","is-referenced-by-count":29,"title":["Epstein-Barr Virus Primary Mismatching and HLA Matching: Key Risk Factors for Post Lung Transplant Lymphoproliferative Disease"],"prefix":"10.1097","volume":"78","author":[{"given":"Jackson Y.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Tait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwyn","family":"Levvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald S.","family":"Esmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory I.","family":"Snell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor J.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom C.","family":"Kotsimbos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210129","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1053-2498(02)00498-9","article-title":"The Registry of the International Society for Heart and Lung Transplantation: Nineteenth Official Report - 2002.","volume":"21","author":"Hertz","year":"2002","journal-title":"J Heart Lung Transplant"},{"key":"R2-8-20210129","first-page":"877","article-title":"Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression.","volume":"10","author":"Armitage","year":"1991","journal-title":"J Heart Lung Transplant"},{"key":"R3-8-20210129","first-page":"S328","article-title":"Incidence and treatment of neoplasia after transplantation.","volume":"12","author":"Penn","year":"1993","journal-title":"J Heart Lung Transplant"},{"key":"R4-8-20210129","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1378\/chest.116.5.1273","article-title":"A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients.","volume":"116","author":"Levine","year":"1999","journal-title":"Chest"},{"key":"R5-8-20210129","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0039-6060(96)80265-0","article-title":"Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation.","volume":"119","author":"Montone","year":"1996","journal-title":"Surgery"},{"key":"R6-8-20210129","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1164\/ajrccm.154.6.8970360","article-title":"Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naive lung transplant recipient.","volume":"154","author":"Aris","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"R7-8-20210129","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1099\/0022-1317-77-6-1169","article-title":"Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients.","volume":"77","author":"Haque","year":"1996","journal-title":"J Gen Virol"},{"key":"R8-8-20210129","first-page":"214","article-title":"Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.","volume":"14","author":"Walker","year":"1995","journal-title":"J Heart Lung Transplant"},{"key":"R9-8-20210129","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S1053-2498(01)00407-7","article-title":"Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients.","volume":"21","author":"Malouf","year":"2002","journal-title":"J Heart Lung Transplant"},{"key":"R10-8-20210129","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2249.1992.tb06414.x","article-title":"Failure of Epstein-Barr virus-specific cytotoxic T lymphocytes to lyse B cells transformed with the B95-8 strain is mapped to an epitope that associates with the HLA-B8 antigen.","volume":"87","author":"Misko","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"R11-8-20210129","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.4049\/jimmunol.149.7.2406","article-title":"Cytotoxic T lymphocytes show HLA-C restricted recognition of EBV-bearing cells and allorecognition of HLA class I molecules presenting self-peptides.","volume":"149","author":"Schendel","year":"1992","journal-title":"J Immunol"},{"key":"R12-8-20210129","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1128\/JVI.67.12.7428-7435.1993","article-title":"HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus through a defined epitope in latent membrane protein LMP2.","volume":"67","author":"Lee","year":"1993","journal-title":"J Virol"},{"key":"R13-8-20210129","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1126\/science.7682013","article-title":"HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population.","volume":"260","author":"De Campos-Lima","year":"1993","journal-title":"Science"},{"key":"R14-8-20210129","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI4225","article-title":"A functional link for major TCR expansions in healthy adults caused by persistent Epstein-Barr virus infection.","volume":"102","author":"Silins","year":"1998","journal-title":"J Clin Invest"},{"key":"R15-8-20210129","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0162-3109(94)90013-2","article-title":"","volume":"27","author":"Schmidt","year":"1994","journal-title":"Immunopharmacol"},{"key":"R16-8-20210129","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S0041-1345(98)00183-3","article-title":"Evidence for a type 2 bias in the CD8+ T-cell response to Epstein-Barr virus following heart transplantation.","volume":"30","author":"Cannon","year":"1998","journal-title":"Transplant Proc"},{"key":"R17-8-20210129","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev.immunol.15.1.405","article-title":"Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection.","volume":"15","author":"Rickinson","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"R18-8-20210129","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1084\/jem.171.1.345","article-title":"An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3).","volume":"171","author":"Burrows","year":"1990","journal-title":"J Exp Med"},{"key":"R19-8-20210129","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1128\/JVI.64.8.3974-3976.1990","article-title":"An Epstein-Barr virus-specific cytotoxic T cell epitope on A- and B-type transformants.","volume":"64","author":"Burrows","year":"1998","journal-title":"J Virol"},{"key":"R20-8-20210129","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.V97.4.835","article-title":"An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.","volume":"97","author":"Gottschalk","year":"2001","journal-title":"Blood"},{"key":"R21-8-20210129","first-page":"173","article-title":"The pathology of post-transplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisolone immunosuppression.","volume":"133","author":"Nalesnik","year":"1988","journal-title":"Am J Pathol"},{"key":"R22-8-20210129","first-page":"1","article-title":"Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group.","volume":"15","author":"Yousem","year":"1996","journal-title":"J Heart Lung Transplant"},{"key":"R23-8-20210129","first-page":"713","article-title":"A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation.","volume":"12","author":"Cooper","year":"1993","journal-title":"J Heart Lung Transplant"},{"key":"R24-8-20210129","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1097\/00007890-200112150-00012","article-title":"Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation.","volume":"72","author":"Wigle","year":"2001","journal-title":"Transplantation"},{"key":"R25-8-20210129","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1097\/01.TP.0000062571.56977.26","article-title":"Risk of lymphoid neoplasia after cardiothoracic transplantation: the influence of underlying disease and human leukocyte antigen type and matching.","volume":"76","author":"Higgins","year":"2003","journal-title":"Transplantation"},{"key":"R26-8-20210129","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S1053-2498(01)00314-X","article-title":"Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases.","volume":"20","author":"Paranjothi","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"R27-8-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/ajcp\/92.2.177","article-title":"The clinical spectrum, pathology, and clonal analysis of Epstein-Barr virus-associated lymphoproliferative disorders in heart-lung transplant recipients.","volume":"92","author":"Randhawa","year":"1989","journal-title":"Am J Clin Pathol"},{"key":"R28-8-20210129","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1002\/(SICI)1097-0142(19980515)82:10<1978::AID-CNCR23>3.0.CO;2-P","article-title":"The morphologic and molecular genetic categories of posttransplant lymphoproliferative disorders are clinically relevant.","volume":"82","author":"Chadburn","year":"1998","journal-title":"Cancer"},{"key":"R29-8-20210129","first-page":"1862","article-title":"Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin.","volume":"147","author":"Chadburn","year":"1995","journal-title":"Am J Pathol"},{"key":"R30-8-20210129","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1136\/jcp.56.6.439","article-title":"Lymphoproliferative disorders in Oxford renal transplant recipients.","volume":"56","author":"Bates","year":"2003","journal-title":"J Clin Pathol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007890-200407270-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:14:03Z","timestamp":1785784443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-200407270-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,27]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004]]}},"URL":"https:\/\/doi.org\/10.1097\/01.tp.0000128611.71038.0c","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7,27]]}}}